Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Nov 1.

Published in final edited form as: Lancet Gastroenterol Hepatol. 2018 Aug 17;3(11):742–753. doi: 10.1016/S2468-1253(18)30231-0

Figure 1. — Network of included studies with the available direct comparisons for (A) induction and (B) maintenance of clinical remission in patients with mild-moderate ulcerative colitis. The size of the nodes and the thickness of the edges are weighted according to the number of studies evaluating each treatment and direct comparison, respectively. In panel A, number corresponds to 1: Placebo/Control, 2: Low-dose mesalamine (<2g), 3: Standard dose mesalamine (2–3g), 4: High-dose mesalamine (>3g), 5: Controlled ileal relelase budesonide, 6: Budesonide MMX, 7: Sulfsalazine, 8: Diazo-bonded 5-aminosalicylates (olsalazine/balsalazide), 9: Oral + Rectal 5-aminosalicylates. In panel B, number corresponds to 1: Placebo/Control, 2: Low-dose mesalamine (<2g), 3: Standard dose mesalamine (2–3g), 4: High-dose mesalamine (>3g), 5: Sulfsalazine, 6: Diazo-bonded 5-aminosalicylates (olsalazine/balsalazide), 7: Oral + Rectal 5-aminosalicylates.

Figure 1. — Network of included studies with the available direct comparisons for (A) induction and (B) maintenance of clinical remission in patients with mild-moderate ulcerative colitis. The size of the nodes and the thickness of the edges are weighted according to the number of studies evaluating each treatment and direct comparison, respectively. In panel A, number corresponds to 1: Placebo/Control, 2: Low-dose mesalamine (<2g), 3: Standard dose mesalamine (2–3g), 4: High-dose mesalamine (>3g), 5: Controlled ileal relelase budesonide, 6: Budesonide MMX, 7: Sulfsalazine, 8: Diazo-bonded 5-aminosalicylates (olsalazine/balsalazide), 9: Oral + Rectal 5-aminosalicylates. In panel B, number corresponds to 1: Placebo/Control, 2: Low-dose mesalamine (<2g), 3: Standard dose mesalamine (2–3g), 4: High-dose mesalamine (>3g), 5: Sulfsalazine, 6: Diazo-bonded 5-aminosalicylates (olsalazine/balsalazide), 7: Oral + Rectal 5-aminosalicylates.